Hospitals Use VigiLanz Software for Compliance With Joint Commission National Patient Safety Goal 3E for Anticoagulation Therapy Safety
Posted on: Monday, 9 June 2008, 15:00 CDT
Joint Commission 2008 National Patient Safety Goal 3E requires hospitals and clinics to implement systems to "reduce the likelihood of patient harm associated with the use of anticoagulation therapy." VigiLanz Corp., which develops the Dynamic Monitoring System to identify and prevent adverse drug events, can help achieve NPSG 3E compliance and optimize a hospital's overall anticoagulation management strategies.
According to the Joint Commission, "Anticoagulation is a high-risk treatment, which commonly leads to adverse drug events due to the complexity of dosing these medications, monitoring their effects, and ensuring patient compliance with outpatient therapy. The use of standardized practices that include patient involvement can reduce the risk of adverse drug events associated with the use of heparin (unfractionated), low molecular weight heparin (LMWH), warfarin, and other anticoagulants."
The Joint Commission requires health care providers to have in place by July 1, 2008, a plan regarding "the resources, assigned responsibilities and time line for full implementation" of 3E compliance. By Oct. 1, 2008, providers are expected to have at least one clinical unit undertaking a pilot test. By January 1, 2009, the process for reducing likelihood of harm from anticoagulation therapy must be fully implemented.
"Without a comprehensive, easy to use system in place to guide and monitor adherence to these new safety standards, hospitals and clinics will likely struggle to comply with these important standardized practices," said Dr. David Goldsteen, CEO of VigiLanz. "Our software is a complete medication safety system that helps health care providers identify, monitor and prevent adverse drug events and adhere to clinical best practices."
At the upcoming Summer Meeting and Exhibition of the American Society of Health-System Pharmacists, the first of several sessions in the "Hot Topics" series is a discussion of the Joint Commission's 2008 National Patient Safety Goals and, specifically, these anticoagulation therapy management requirements. Representatives from VigiLanz will be attending the ASHP conference and demonstrating the company's software at booth 840 on the exhibition floor.
About VigiLanz
VigiLanz Corporation was founded in 2001 by two medical doctors seeking to empower pharmacists, physicians and nurses with tools to proactively monitor their patients to identify and prevent adverse drug events, and to support adherence to clinical best practices. Prevention remains one of the core benefits of the VigiLanz Dynamic Monitoring System, an automated 24/7 patient monitoring system that enables real-time patient safety monitoring and can reduce preventable ADEs and other adverse events by 50 percent or more. The Dynamic Monitoring System is the first comprehensive, rules-based software that merges the patient's clinical data with the hospital's own clinical best-practice guidelines to empower clinicians to anticipate, identify and prevent adverse events and optimize clinical outcomes. (www.vigilanzcorp.com)
Media contact: Michael Keliher 651-695-0174 - office 651-324-0213 - cell mkeliher@providentpartners.net
SOURCE: VigiLanz
Source: MARKET WIRE
Related Articles
- Discussing Adverse Events With Patients Improves How They Rate Their Hospital Care
- SRA Selects Oracle(R) Adverse Event Reporting System
- Woman's Hospital Selects rL Solutions for Improved Adverse Event and Patient Safety Reporting
- Drug Index Safety System--New Drug Labeling System Eliminates Medication Error at Patient Bedside
- The Drug Index Safety System Can Help Pharmaceutical Companies Pressed to Meet California Mandate
- Minn. Health System Purges Hospitals and Clinics of Drug Company Trinkets
- ICU Patients at Significant Risk for Adverse Events and Serious Errors
- The Incidence of Upper Gastrointestinal Adverse Events in Clinical Trials of Etoricoxib Vs. Non-Selective NSAIDs: an Updated Combined Analysis*
- Psychiatric Effects of Ephedra Use: An Analysis of Food and Drug Administration Reports of Adverse Events
- Monitoring Drug Safety
 |
 |
User Comments (1)
| 1. |
Posted by James Goldberg on 06/12/2008, 10:26 If you really want to KNOW about the JOINT COMMISSION...take 20 minutes and review these clips! James Goldberg San Francisco and New York 415 686 7139 This is part of a documentary which will soon be aired in Europe. Part One: http://video.google.com/videoplay?docid=2541172325991739673 Part Two: http://video.google.com/videoplay?docid=-4774600238421011332 Part Three: http://video.google.com/videoplay?docid=8546130908978679014 |
RSS Feeds